Literature DB >> 12023610

Multiple pathways to allograft rejection.

Alain Le Moine1, Michel Goldman, Daniel Abramowicz.   

Abstract

Allograft rejection results from a complex process involving both the innate and acquired immune systems. The innate immune system predominates in the early phase of the allogeneic response, during which chemokines and cell adhesion play essential roles, not only for leukocyte migration into the graft but also for facilitating dendritic and T-cell trafficking between lymph nodes and the transplant. This results in a specific and acquired alloimmune response mediated by T cells. Subsequently, T cells and cells from innate immune system function synergistically to reject the allograft through nonexclusive pathways, including contact-dependent T cell cytotoxicity, granulocyte activation by either Th1 or Th2 derived cytokines, NK cell activation, alloantibody production, and complement activation. Blockade of individual pathways generally does not prevent allograft rejection, and long-term allograft survival is achieved only after simultaneous blockade of several of them. In this review, we explore each of these pathways and discuss the experimental evidence highlighting their roles in allograft rejection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12023610     DOI: 10.1097/00007890-200205150-00001

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  43 in total

1.  Critical role of the Toll-like receptor signal adaptor protein MyD88 in acute allograft rejection.

Authors:  Daniel R Goldstein; Bethany M Tesar; Shizuo Akira; Fadi G Lakkis
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

2.  Loss of transgene following ex vivo gene transfer is associated with a dominant Th2 response: implications for cutaneous gene therapy.

Authors:  Zhenmei Lu; Soosan Ghazizadeh
Journal:  Mol Ther       Date:  2007-03-13       Impact factor: 11.454

Review 3.  The innate immune system in allograft rejection and tolerance.

Authors:  David F LaRosa; Adeeb H Rahman; Laurence A Turka
Journal:  J Immunol       Date:  2007-06-15       Impact factor: 5.422

4.  Anti-inflammatory effects of alphav integrin antagonism in acute kidney allograft rejection.

Authors:  Jens Bedke; Eva Kiss; Carl-Ludwig Behnes; Zoran V Popovic; Markus Heuser; Tomislav Stojanovic; Tjeerd Sijmonsma; Peter Huber; Sophie Domhan; Stefan Muschal; Amir Abdollahi; Norbert Gretz; Hermann-Josef Gröne
Journal:  Am J Pathol       Date:  2007-08-16       Impact factor: 4.307

5.  Trichinella spiralis infection changes immune response in mice performed abdominal heterotopic cardiac transplantation and prolongs cardiac allograft survival time.

Authors:  Gengguo Deng; Ronghai Deng; Jianping Yao; Bing Liao; Yinghua Chen; Zhongdao Wu; Hongxing Hu; Xingwang Zhou; Yi Ma
Journal:  Parasitol Res       Date:  2015-10-19       Impact factor: 2.289

Review 6.  Impact of hyperlipidemia on alloimmunity.

Authors:  Jessamyn Bagley; Jin Yuan; John Iacomini
Journal:  Curr Opin Organ Transplant       Date:  2017-02       Impact factor: 2.640

7.  Identification of novel Interleukin-2 inhibitors through computational approaches.

Authors:  Sobia Ahsan Halim; Omer Mohamed Abdalla; M Ahmed Mesaik; Abdul Wadood; Zaheer ul-Haq; Maria Kontoyianni
Journal:  Mol Divers       Date:  2013-03-14       Impact factor: 2.943

8.  Transplant acceptance following anti-CD4 versus anti-CD40L therapy: evidence for differential maintenance of graft-reactive T cells.

Authors:  S C Wood; G Lu; B E Burrell; D K Bishop
Journal:  Am J Transplant       Date:  2008-10       Impact factor: 8.086

9.  Standardization and cross validation of alloreactive IFNγ ELISPOT assays within the clinical trials in organ transplantation consortium.

Authors:  I Ashoor; N Najafian; Y Korin; E F Reed; T Mohanakumar; D Ikle; P S Heeger; M Lin
Journal:  Am J Transplant       Date:  2013-05-24       Impact factor: 8.086

10.  Rapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cells.

Authors:  Chen Wang; Tai Yi; Lingfeng Qin; Roberto A Maldonado; Ulrich H von Andrian; Sanjay Kulkarni; George Tellides; Jordan S Pober
Journal:  J Clin Invest       Date:  2013-03-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.